Literature DB >> 33334462

Acute Kidney Injury in Sepsis: Evidence From Asia.

Kohei Yoshimoto1, Yohei Komaru2, Masao Iwagami3, Kent Doi4.   

Abstract

Acute kidney injury (AKI) is one of the most frequent complications of sepsis. Because sepsis and AKI synergistically worsen the outcomes of critically ill patients, better therapeutics against septic AKI urgently are required. In addition to the complexity of disease mechanisms of both sepsis and AKI, there is substantial regional variation in clinical practice, which further hampers the development of new treatments for septic AKI. To overcome this problem, evidence accumulation is necessary for building the foundation for developing novel septic AKI treatments. This review provides a summary of updated evidence regarding septic AKI from Asian regions.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Acute kidney injury; adsorption; endotoxin adsorption; epidemiology; sepsis

Year:  2020        PMID: 33334462     DOI: 10.1016/j.semnephrol.2020.08.005

Source DB:  PubMed          Journal:  Semin Nephrol        ISSN: 0270-9295            Impact factor:   5.299


  3 in total

1.  Erythropoietin promotes energy metabolism to improve LPS-induced injury in HK-2 cells via SIRT1/PGC1-α pathway.

Authors:  Kan Li; Li Gao; Sen Zhou; Yan-Rong Ma; Xiao Xiao; Qian Jiang; Zhi-Hong Kang; Ming-Long Liu; Tian-Xi Liu
Journal:  Mol Cell Biochem       Date:  2022-08-24       Impact factor: 3.842

2.  The Potential of miR-370-3p and miR-495-3p Serving as Biomarkers for Sepsis-Associated Acute Kidney Injury.

Authors:  Wenlu Ma; Xiaomei Miao; Fangfang Xia; Chao Ruan; Dan Tao; Bing Li
Journal:  Comput Math Methods Med       Date:  2022-07-11       Impact factor: 2.809

3.  Transcriptomic analysis and laboratory experiments reveal potential critical genes and regulatory mechanisms in sepsis-associated acute kidney injury.

Authors:  Boyang Liu; Shengxiang Ao; Fang Tan; Wei Ma; Haoru Liu; Huaping Liang; Xia Yang; Xinjin Chi
Journal:  Ann Transl Med       Date:  2022-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.